Non-alcoholic Steatohepatitis (NASH) Treatment Market Size & Share, by Drug Type (Vitamin E, Pioglitazone, Obeticholic Acid, Lanifibranor, Semaglutide, Resmetirom, Aramchol); Distribution Channel (Hospital Pharmacies, Retail & Specialty Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4695
  • Published Date: Aug 09, 2023
  • Report Format: PDF, PPT

 

Global Market Size, Forecast, and Trend Highlights Over 2023 - 2035

Non-alcoholic Steatohepatitis Treatment Market size is anticipated to reach USD 48.3 Billion by the end of 2035, growing at a CAGR of 18% during the forecast period, i.e., 2023 – 2035. In the year 2022, the industry size of non-alcoholic steatohepatitis treatment was over USD 5.2 Billion. The growth of the market is attributed to the growing number of obese people. Obesity is the main cause of fatty liver problems as it increases the accumulation of fatty tissue in the liver. In the United States, about 42% of people are obese, with black adults being about 50% fatter.

Additionally, Indians are more likely to be obese in 2019–21 than in 2015–2016. Compared to one in five people in the past, about one in four is overweight today. In addition, positive results from clinical trials of therapeutic drugs are believed to be among the factors driving the growth of the non-alcoholic steatohepatitis (NASH) drugs market. For example, traces in an analysis of Intercept's phase 3 recovery study of obeticholic acid showed that some positive substances, such as B. OCA 25 mg, achieved important goals of improving liver fibrosis without worsening NASH. In addition, OCA 25 mg demonstrated a double response rate in reducing liver fibrosis without worsening NASH compared to placebo.


Non-alcoholic Steatohepatitis Treatment
Get more information on this report: Request Free Sample PDF

Non-alcoholic Steatohepatitis Treatment Market: Growth Drivers and Challenges

Growth Drivers

  • Rising Cases of Obesity– NASH tend to develop in the people who are overweight or at a risk of obesity. As per the data of the World Health Organization, around the world, 650 million adults, 340 million teenagers, and 39 million children are obese. Moreover, this count is expected to continuously rise owing to the unhealthy lifestyle of people. It is anticipated that by 2025, there are likely be 167 million adults and children living with obesity.
  • Growing Burden of Liver Disease With a 25% global prevalence, nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease. In addition to liver fat, NASH is a variant of NAFLD in which the liver is also inflamed and damaged.
  • Growing Success of Medication Developed for NASH- For instance, Madrigal Pharmaceuticals developed a drug, Resmetirom for NASH. In its trial, around 26% of individuals who received the medication in an 80 mg dose had their NASH resolved.

Challenges

  • Difficulty faced during the formulation of the drugs- The development of drugs for the treatment of NASH can be tedious since liver fibrosis develops slowly and gradually over many years or decades. The level of benefit from a patient's lifetime treatment for NASH must be weighed against the drug's safety profile. As NASH patients are also susceptible to other illnesses, the drug treatment should be developed while keeping in mind the other issues including cardiovascular disease, hyperlipidemia, metabolic disease, and diabetes.
  • Patients with NASH are susceptible to abnormalities
  • Large size of population with NASH is still under-diagnosed

Non-alcoholic Steatohepatitis Treatment: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

~18%

Base Year Market Size (2022)

~ USD 5.2 Billion

Forecast Year Market Size (2035)

~ USD 48.3 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Non-alcoholic Steatohepatitis Treatment Segmentation

Drug Type (Vitamin E and Pioglitazone, Obeticholic Acid, Lanifibranor, Semaglutide, Resmetirom, Aramchol, Others)

The vitamin E and pioglitazone segment in the non-alcoholic steatohepatitis treatment market is estimated to gain the largest revenue share in the year 2035. The growth of the segment can be attributed to the increasing effectiveness of vitamin E and pioglitazone in treating NASH patients. In an experiment of using pioglitazone for treating 52 NASH patient with type-II diabetes and 49 with prediabetes. The result showed that compared to 46% of patients without diabetes, 48% of type 2 diabetes patients achieved the primary outcome. Compared to 26% of people without type 2 diabetes, resolution of NASH was achieved in 44% of those patients. On the other hand, few experiments have shown that a dose of 800 IU per day of vitamin E is beneficial for active NASH adult patients without any form of diabetes.

Distribution Channel (Hospital Pharmacies, Retail & Specialty Pharmacies)

Non-alcoholic steatohepatitis treatment market from the retail & specialty pharmacies segment is expected to garner a significant share in the year 2035. NASH is an chronic disease that forces patient to be on medication for a very long period, that boost the sales of NASH drugs from the retail pharmacies. NASH therapeutic should be continuously received by the patient otherwise it can lead to severe issues, such as liver failure, liver transplantation, and even liver cancer. In the cases of liver cancer, NASH is combined with liver cancer therapeutics which reduces its efficacy. Therefore, it is important to continue the course of drugs for NASH. The segment growth is major attributed to homecare facilities that are connected to retail pharmacies, which in turn boost the demand for off-label drugs. Few pharmaceutical corporations have indicated that the total medication market for NASH is worth around USD 35 Billion.

Our in-depth analysis of the global NASH treatment market includes the following segments:

       

           Distribution Channel

  • Hospital Pharmacies
  • Retail & Specialty Pharmacies

 

   

           Drug   Type          

  • Vitamin E and Pioglitazone
  • Obeticholic Acid
  • Lanifibranor
  • Semaglutide
  • Resmetirom
  • Aramchol
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Non-alcoholic Steatohepatitis Treatment Industry - Regional Synopsis

North American Market Forecast

The non-alcoholic steatohepatitis treatment market in the North American region is projected to hold the largest market share of 40% by the end of 2035. The growth of the market can be attributed majorly to the rising cases of non-alcoholic fatty liver diseases. Around 80 million to 100 million Americans are affected by non-alcoholic fatty liver disease. It has become the leading cause for liver transplant, surpassing hepatitis C. Moreover, out of total people suffering with NAFLD, around 30 million are affected by specifically non-alcoholic steatohepatitis (NASH). Additionally, the rising expenditure on the treatment of NASH patients is expected to boost the market growth in North America. The annual healthcare expense for NASH in the United States is around USD 5 billion. The expenditure entails various facilities, including testing, treatment, transplants, and hospitalization.

European Market Statistics

The non-alcoholic steatohepatitis treatment market in the Europe region is projected to hold the second largest share during the forecast period. The segment is expected to grow at a CAGR of 18.6% over the forecast period. Moreover, the market in Europe generated a revenue of USD 1,485.7 million in 2022. The market growth in the region is credited to the rise in the size of the obese population. According to the WHO European Regional Obesity Report 2022, 59% of adults and roughly one in three children (29% of boys and 27% of girls) in the region are overweight or obese.

Research Nester
Non-alcoholic Steatohepatitis Treatment Market
Get more information on this report: Request Free Sample PDF

Companies Dominating the Non-alcoholic Steatohepatitis Treatment Landscape

top-features-companies
    • Intercept Pharmaceuticals, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Pfizer, Inc.
    • Inventiva
    • Galmed Pharmaceuticals Ltd.
    • Novo Nordisk A/S
    • Madrigal Pharmaceuticals
    • Galectin Therapeutics
    • NGM Biopharmaceuticals
    • Brsitol-Myers Squibb Company
    • Can Fite
    • Zydus Lifesciences Ltd.
    • Mitsubishi Chemical Group Corporation

In-the-news

In The News

  • Novo Nordisk A/S announced the extension of their collaboration with Gilead Sciences, Inc. for clinical trials in non-alcoholic steatohepatitis (NASH). The companies plans to carry out a phase 2b double-blind, placebo-controlled study to examine the safety and effectiveness of semaglutide, a GLP-1 receptor agonist from Novo Nordisk, and a fixed-dose combination of cilofexor, an investigational FXR agonist, and firsocostat, an investigational ACC inhibitor.
  • Pfizer, Inc. announces the fast track designation grant from U.S. Food and Drug Administration (FDA) to company’s investigational combination medication for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. This will speed up the review process and make it easier to create new medications and vaccines that are meant to treat or prevent serious illnesses and meet unmet medical needs.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4695
  • Published Date: Aug 09, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing incidences of NAFLD is the major factor driving the market growth.

The market size of non-alcoholic steatohepatitis treatment is anticipated to attain a CAGR of 18% over the forecast period, i.e., 2023 – 2035.

The major players in the market are Pfizer, Inc., Inventiva, Galmed Pharmaceuticals Ltd., Novo Nordisk A/S, Madrigal Pharmaceuticals, Galectin Therapeutics, NGM Biopharmaceuticals, Brsitol-Myers Squibb Company, Can Fite, Zydus Lifesciences Ltd., Mitsubishi Chemical Group Corporation, and others.

The vitamin E and pioglitazone segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Non-alcoholic Steatohepatitis Treatment Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying